600671.SS SHH
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd
1W: -8.8%
1M: -4.7%
3M: +21.8%
YTD: +8.0%
1Y: +46.1%
3Y: +165.4%
5Y: +164.8%
¥21.79 ($3.25)
+0.17 (+0.79%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
Cash Flow Trends
Operating Cash Flow
-$37M
-79.5% ▼
Capital Expenditures
$21M
-129.5% ▼
5Y CAGR: -26.3%
Free Cash Flow
-$57M
-94.8% ▼
Dividends Paid
$9M
-28.8% ▼
Buybacks
$0
+0.0% ▲
Net Change in Cash
-$50M
-190.9% ▼
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | -$52M | -$33M | -$73M | -$39M | $22M |
| Depreciation & Amort. | $9M | $12M | $18M | $15M | $19M |
| Stock-Based Comp. | $0 | $0 | $0 | $0 | $0 |
| Change in Working Capital | -$15M | -$30M | -$6M | -$13M | -$90M |
| Other Non-Cash Items | $49M | $24M | $42M | $17M | $13M |
| Operating Cash Flow | -$8M | -$26M | -$19M | -$20M | -$37M |
| — Investing Activities — | |||||
| Capital Expenditures | -$12M | -$5M | -$4M | -$9M | -$21M |
| Acquisitions (Net) | $3M | $555K | -$2M | $0 | -$6M |
| Investment Purchases | -$13M | $0 | $0 | $0 | $0 |
| Investment Sales | $12M | $0 | $0 | $0 | $0 |
| Other Investing | -$753K | $0 | -$82K | $129K | $30 |
| Investing Cash Flow | -$11M | -$4M | -$6M | -$9M | -$27M |
| — Financing Activities — | |||||
| Net Debt Issuance | $0 | -$44M | -$5M | -$105K | $24M |
| Stock Repurchased | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | -$7M | -$7M | -$5M | -$7M | -$9M |
| Other Financing | $15M | $85M | $65M | $92M | -$3M |
| Financing Cash Flow | $8M | $35M | $56M | $85M | $13M |
| Net Change in Cash | -$12M | $4M | $31M | $56M | -$50M |
| Cash End of Period | $8M | $12M | $42M | $98M | $47M |
| Free Cash Flow | -$20M | -$31M | -$23M | -$29M | -$57M |